Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

31.62 +0.77 (+2.50%)
Streaming Delayed Price Updated: 1:38 PM EDT, May 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 153,871
Open 31.01
Bid (Size) 31.56 (100)
Ask (Size) 31.66 (100)
Prev. Close 30.85
Today's Range 30.89 - 32.24
52wk Range 18.55 - 35.79
Shares Outstanding 66,344,236
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Via Chartmill
Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup ↗
Via Chartmill

Performance

YTD
+17.1%
+17.1%
1 Month
-6.1%
-6.1%
3 Month
+27.3%
+27.3%
6 Month
+19.6%
+19.6%
1 Year
+59.9%
+59.9%

More News

Read More
News headline image
Celldex Reports First Quarter Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex to Present at Upcoming Investor Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Proposed Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
Via The Motley Fool
News headline image
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗
Via Stocktwits
Topics Earnings
News headline image
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics SVPs Engage In Heavy Transactions ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗
Via Benzinga
News headline image
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Celldex Therapeutics, Inc. - Common Stock publicly traded?
Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?
Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?
The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market
What is the current price of Celldex Therapeutics, Inc. - Common Stock?
The current price of Celldex Therapeutics, Inc. - Common Stock is 31.62
When was Celldex Therapeutics, Inc. - Common Stock last traded?
The last trade of Celldex Therapeutics, Inc. - Common Stock was at 05/27/26 01:38 PM ET
What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?
The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 2.10B
How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?
Celldex Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.